Khosla Ventures

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026

Khosla Ventures funds technology companies at seed, early and growth stages, including businesses tackling difficult scientific and engineering problems in energy, industry, healthcare and software.

Its investments in fusion and lower-emission cement illustrate an appetite for technical risk in markets where commercialisation requires more than a software launch. The firm also invests in AI and developer businesses, applying the same interest in technology that can change how an industry works.

Its Venture Assistance programme includes candidate shortlists, compensation and hiring-close materials, recruiting events and operator office hours in growth, product marketing, data and sales. Those are practical resources for founders assembling the team and commercial capability around a technical product.

Sources
Rounds participated in
6
Confirmed lead rounds
0
5 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$445M
5 disclosed · full round size, not this investor’s share

By stage

Series C+2
Seed1
Series A1
Series B1
Undisclosed1

By primary sector

Biotech3
Healthtech2
Enterprise software1

By country

United States5
United Kingdom1

Rounds

6 in this selection
Moonwalk Biosciences

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

$70MSeries B
Participant
Pramaana Labs

Builds formal verification tools ensuring AI reliability in law, drug discovery, and tax prep

$27MSeed
Role not disclosed
Novellia

Platform that unifies patient health records for individuals and supplies anonymized data to pharma researchers

$18MSeries A
Role not disclosed
Folly

Develops biotech-powered hair supplements using proprietary microencapsulation

UndisclosedFollow-On
Role not disclosed
Science Corporation

Develops brain-computer interface retinal implants to restore vision in patients with retinal diseases

$230MSeries C
Role not disclosed
Loyal

Loyal develops medicines intended to extend dogs’ lifespans.

$100MSeries C
Role not disclosed